Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 15;87(10):908-915.
doi: 10.1016/j.biopsych.2019.12.013. Epub 2020 Jan 8.

Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalized Anxiety Disorder

Affiliations

Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalized Anxiety Disorder

Toby Wise et al. Biol Psychiatry. .

Abstract

Background: Generalized anxiety disorder is associated with hyperactivity in the amygdala-prefrontal networks, and normalization of this aberrant function is thought to be critical for successful treatment. Preclinical evidence implicates cholinergic neurotransmission in the function of these systems and suggests that cholinergic modulation may have anxiolytic effects. However, the effects of cholinergic modulators on the function of anxiety-related networks in humans have not been investigated.

Methods: We administered a novel α7 nicotinic acetylcholine receptor-negative allosteric modulator, BNC210, to 24 individuals (3 male subjects) with generalized anxiety disorder and assessed its effects on neural responses to fearful face stimuli.

Results: BNC210 reduced amygdala reactivity to fearful faces relative to placebo and similarly to lorazepam and also reduced connectivity between the amygdala and the anterior cingulate cortex, a network involved in regulating anxious responses to aversive stimuli.

Conclusions: These results demonstrate for the first time that the function of disorder-relevant neural circuits in generalized anxiety disorder can be beneficially altered through modulation of cholinergic neurotransmission and suggest potential for this system as a novel target for anxiolytic pharmacotherapy.

Keywords: Amygdala; Anterior cingulate cortex; Cholinergic modulation; Generalized anxiety disorder; Pharmacotherapy; fMRI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Illustration of the four dosing procedures. MRI, magnetic resonance imaging.
Figure 2
Figure 2
(A) Mean (±SE) amygdala response to fearful faces for each drug condition. (B) Effect of BNC210 low dose on amygdala activity, thresholded at p < .05 uncorrected for illustration. *p < .05, **p < .01.
Figure 3
Figure 3
(A) Mean functional connectivity strength with amygdala seeds while viewing fearful faces in the anterior cingulate cortex cluster. (B) Anterior cingulate cortex cluster showing significant reductions in functional connectivity strength with the amygdala under BNC210 (low dose) in the psychophysiological interaction analysis.

References

    1. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:593–602. - PubMed
    1. Katzman M.A. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs. 2012;23:103–120. - PubMed
    1. Schweizer E., Rickels K. Benzodiazepine dependence and withdrawal: A review of the syndrome and its clinical management. Acta Psychiatr Scand. 1998;98:95–101. - PubMed
    1. Etkin A., Prater K.E., Hoeft F., Menon V., Schatzberg A.F. Failure of anterior cingulate activation and connectivity with the amygdala during implicit regulation of emotional processing in generalized anxiety disorder. Am J Psychiatry. 2010;167:545–554. - PMC - PubMed
    1. Nitschke J.B., Sarinopoulos I., Oathes D.J., Johnstone T., Whalen P.J., Davidson R.J., Kalin N.H. Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry. 2009;166:302–310. - PMC - PubMed

Publication types

Substances